Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.
A 35-year-old transitioning female (MtF) shared her hair regrowth journey using Minoxidil, Dutasteride, Microneedling, and Exosomes, starting from a bald state. Commenters discussed the impressive results, skin care routine, and the effects of estrogen on hair and skin.
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
A user reports using Hims (with finasteride and minoxidil), Kirkland Minoxidil 5%, RU58841, and derma stamping for hair loss and seeks feedback on their 9-week progress, particularly for growth around the temples and crown.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.
The user "StrummerBummer" has been taking finasteride for 25 years without side effects, but is now switching to dutasteride. Other users congratulate and support the decision.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks opinions on the effectiveness of these treatments.
Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.
The conversation discusses the use of dutasteride and finasteride for hair loss, including switching between them, optimal dosing, and managing side effects. The user has transcriptions of videos on these topics and offers them to others interested.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.
A user discusses their extensive hair loss treatment regimen, which includes dutasteride, oral and topical minoxidil, RU58841, various supplements, and lifestyle changes. The conversation includes opinions on the effectiveness and necessity of such a comprehensive approach, with some users suggesting alternatives like microneedling and questioning the high dosage of dutasteride.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.
A user's transformation from an accountant to a spartan with a full beard, discussing the potential of DUPA and alopecia areata, as well as treatments like vitamins, topicals, and natural treatments for potential regrowth.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
User experienced hair growth after 6 months using microneedling, minoxidil, ketoconazole, and biotin. Commenters suggest adding finasteride to treatment for better results and preventing further hair loss.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
The conclusion of the conversation is that the user, PirateBeastBaby, had good results with microneedling for hair loss after using oral finasteride and topical minoxidil 20 years ago. They believe that microneedling was the gamechanger for their hair growth.
Dutasteride capsules were exposed to heat and humidity, causing them to soften, and the user considered replacing them with new ones from a local pharmacy. Suggestions included alternating between old and new capsules, storing them properly, and using them topically with Minoxidil, though the user decided to wait and see the effects of Dutasteride first.
A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
The conversation is about a user who started using finasteride to address crown balding, noticing reduced hair shedding and halted progression of male pattern baldness. The user also used a dermal stamp and expressed optimism about potential regrowth, despite a slight decrease in libido.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.